Session Item

·  To analyse incidence of COVID-19 in patients across different Spain centers.To study the impact of treatment interruptions in Colorectal, Head & Neck,Lung,Urological, Gynecological, Breast, lymphomas and metastases cancers. 

A retrospective, observational and multicenter study was carried out in 13 medical centers. We recollected through the records of notification to the COVID-19 committee (suspected patients or confirmed, in treatment or about to start) from January 2020 to September 1, 2021 (20 months).  Besides to the sociodemographic data collected, information related to the treatment and location of the tumor was recorded, grouped into 6 different groups: head and neck, chest (breast and lymphoma), lung, urological, abdomen (rectum, gynecological and superior abdomen) and metastasis.We compiled the temporary or definitive interruption in treatments.  A univariate analysis and Cox regressions was performed between treatment interruption and sociodemographic (sex, age) and treatment-related factors (tumor site, radiotherapy intention and sequence, systemic treatment).Different waves were defined during the pandemic: 1st wave from January to March 2020; 2nd wave, from September to December 2020; 3rd wave, from January to March 2021; 4rth wave, from April to May 2021; 5th wave, from June to August 2021. 

12,484 first consultations were visited from January 2020 to August 2021 in 13 centers. 63 (0.005%) patients were included in the study (42.86% women, mean age= 66.94, SD = 9.67).Incidence rate was 5.05/100,000 inhabitants. As a result, the highest incidence reported, were in the first wave (13.22) and in the third wave (9.16). (figure 1). The highest incidence rate was in Madrid centers (46.03%). COVID-19 disease was confirmed by a positive PCR test in 63.46% patients.The relationship between radiotherapy sequence and interruption risk was endorsed, observing higher risk of treatment interruption in patients with concomitant treatment (p < .05). On the other hand, Cox regression revealed a significant relationship between age (OR = 0.94, p < .05). Patients with temporary suspension had a mean age of 65.12 (sd = 8.64) and those who did not have temporary suspension, mean age = 67.41 (sd = 9.93).Finally, patients with gynecological or rectal cancers showed higher risk of temporary treatment in interruption comparison to those with breast or hematological cancers (OR = 7.58, p < .05).

COVID-19 incidence has been very low across our centers, with an incidence rate of 5.05 per 100,000 inhabitants. The results showed a temporal interruption of treatment with radiotherapy and/or chemotherapy in younger patients, and both the temporary and definitive interruption of oncological treatment were more frequent in the group of patients receiving concomitant treatment. Pathologies with less hypofractionated treatment schemes (gynecological and rectum) have a higher risk of interruption.